Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD and MAD study of VES001
NL-OMON59829Phase 1Completed
- Sponsor
- Insusense Therapeutics
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of VES001 in frontotemporal dementia (FTD), sponsored by Insusense Therapeutics. Primary endpoint: Primary endpoint(s). Started Oct 2023; status: completed.
02
Drugs
VES001
03
Conditions
frontotemporal dementia (FTD)
Beyond the preview
Go deeper on NL-OMON59829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59829.